A BILL 
To amend the Controlled Substances Act to deem drugs 
or other substances that act as mu opioid receptor 
agonists to be in schedule I, subject to exceptions for 
substances intended for legitimate medical or research 
use, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Modernizing Drug En-
4
forcement Act of 2019’’. 
5
05:26 May 14, 2019
\\ALPHA3\E\BILLS\H2580.IH
H2580
2 
•HR 2580 IH
SEC. 2. DRUGS OR OTHER SUBSTANCES THAT ACT AS MU 
1
OPIOID RECEPTOR AGONISTS. 
2
(a) DEFINITIONS.—Paragraph (18) of section 102 of 
3
the Controlled Substances Act (21 U.S.C. 802) is amend-
4
ed to read as follows: 
5
‘‘(18)(A) The term ‘opiate’or ‘opioid’— 
6
‘‘(i) means any drug or other substance having 
7
an addiction-forming or addiction-sustaining liability 
8
similar to morphine or being capable of conversion 
9
into a drug having such addiction-forming or addic-
10
tion-sustaining liability; and 
11
‘‘(ii) includes any drug or other substance that 
12
acts as a mu opioid receptor agonist. 
13
‘‘(B) The term ‘mu opioid receptor’ is a molecule that 
14
when bound to, and activated by, a mu opioid receptor 
15
agonist would result in analgesia, euphoria, addiction, or 
16
respiratory depression in the central nervous system. 
17
‘‘(C) The term ‘mu opioid receptor agonist’ is a sub-
18
stance that when bound to, and interacting with, the mu 
19
opioid receptor, activates the receptor to result in analge-
20
sia, euphoria, addiction, or respiratory depression.’’. 
21
(b) SCHEDULING.—Section 201 of the Controlled 
22
Substances Act (21 U.S.C. 811) is amended by adding at 
23
the end the following: 
24
‘‘(k) MU OPIOID RECEPTOR AGONISTS.— 
25
05:26 May 14, 2019
\\ALPHA3\E\BILLS\H2580.IH
H2580
3 
•HR 2580 IH
‘‘(1) IN GENERAL.—Effective as of the date of 
1
enactment of the Modernizing Drug Enforcement 
2
Act of 2019, schedule I under section 202 is deemed 
3
to include, unless specifically exempted or unless 
4
listed in another schedule, any chemical substances, 
5
including their salts, isomers, and salts of isomers 
6
whenever the existence of such salts, isomers, and 
7
salts of isomers is possible, that act as mu opioid re-
8
ceptor agonists, and any material, compound, mix-
9
ture, or preparation that contains any quantity of 
10
such substances. 
11
‘‘(2) EXCEPTIONS.—A chemical substance is ex-
12
empt from inclusion in schedule I by operation of 
13
paragraph (1)— 
14
‘‘(A) if the substance is the subject of an 
15
approved application submitted under sub-
16
section (b) or (j) of section 505 of the Federal 
17
Food, Drug, and Cosmetic Act; 
18
‘‘(B) to the extent the substance is exempt 
19
from the provisions of section 505 of such Act 
20
relating to new drugs because— 
21
‘‘(i) the substance is intended solely 
22
for investigational use as described in sec-
23
tion 505(i) of such Act; and 
24
05:26 May 14, 2019
\\ALPHA3\E\BILLS\H2580.IH
H2580
4 
•HR 2580 IH
‘‘(ii) the substance is being used ex-
1
clusively for purposes of a clinical trial 
2
that is the subject of an effective investiga-
3
tional new drug application; or 
4
‘‘(C) to the extent the substance is the 
5
subject of a nonclinical study by researchers 
6
qualified by scientific training to investigate the 
7
safety and effectiveness of drugs. 
8
‘‘(3) LISTING.—Not later than 180 days after 
9
the date of enactment of the Modernizing Drug En-
10
forcement Act of 2019, the Attorney General shall 
11
update schedule I in accordance with paragraph (1). 
12
The Attorney General may list substances in sched-
13
ule I pursuant to paragraph (1) without regard to 
14
the process and considerations that are otherwise 
15
applicable under this section for adding, removing, 
16
or transferring controlled substances to, from, or 
17
among the schedules under section 202.’’. 
18
Æ 
05:26 May 14, 2019
\\ALPHA3\E\BILLS\H2580.IH
H2580
